Shares of Intuitive Surgical, Inc. (ISRG) fell about 8% in premarket trading on Wednesday, dropping to roughly $405, after the surgical robotics company reported third-quarter results that beat Wall Street estimates but came with a $450 million legal charge and new detail on planned price reductions. The reaction reflected how, for a company whose recurring instrument sales ride on procedure volumes, legal and pricing details carried as much weight as the headline numbers themselves.

The stock had closed Tuesday up 1.1%. It is now down about 23% in 2026, putting it on pace for its worst year since 2022.

Adjusted earnings came in at $3.00 per share, well above the $2.65 consensus, while revenue rose 22% from a year earlier to $3.05 billion, ahead of the $2.91 billion estimate.

A summary of the quarter's headline metrics shared by Wall St Engine on X:

INTUITIVE SURGICAL $ISRG Q3'26 EARNINGS HIGHLIGHTS 🔹 Revenue: $3.05B (Est. $2.91B) 🟢; +22% YoY 🔹 Adj. EPS: $3.00 (Est. $2.64) 🟢; +25% YoY 🔹 GAAP EPS: $1.49; -24% YoY 🔹 Adj. Gross Margin: 69.9% FY26 Guide: 🔹 da Vinci Procedure Growth: ~+14%-+15% 🔹 Adj. Gross Margin:… pic.twitter.com/iI8NEP5G8a

— Wall St Engine (@wallstengine) October 20, 2026

Per that summary, adjusted EPS grew 25% year over year, GAAP EPS declined 24%, and adjusted gross margin stood at 69.9%. The earnings-per-share estimate cited in the post was $2.64, while consensus figures cited elsewhere put it at $2.65.

The slide came despite the beat, as investors looked past the headline numbers and zeroed in on what accompanied them.

The Settlement Weighs on Profit

Intuitive agreed to pay $450 million to settle the da Vinci antitrust class action. The case dates back to 2021, when hospital operators accused the company of anticompetitive practices tied to the servicing and repair of instruments. Intuitive did not admit wrongdoing, and the settlement still requires court approval. That review leaves final sign-off and payout timing open, and if approved, the agreement would close a dispute that has run since 2021.

The charge cut third-quarter reported earnings by 99 cents per share. GAAP net income fell to $523 million, or $1.49 per diluted share, from $704 million, or $1.95 per share, a year earlier.

Pricing Cuts and Slower U.S. Growth

On the earnings call, management put numbers on planned price reductions. These include an extended-use instrument program in the United States and a price cut in China that begins in November. Together, the measures are expected to lower instrument and accessory revenue per procedure by about 3% to 5% once fully in place in 2027, on a mix-constant basis. Because instruments and accessories are consumed with each procedure performed on the installed base, they form the core of the company's recurring revenue — which is why the guidance drew attention quickly, and why the November start of the China cut offers an early checkpoint on how quickly the changes reach reported results.

U.S. da Vinci procedure growth came in at 10%, the softest domestic since the COVID era. International procedures grew 20%, and total procedures rose 15%.

The company narrowed its 2026 worldwide procedure growth forecast to 14% to 15%, from a prior range of 13.5% to 15.5%, with management expecting growth near the midpoint of the new range — a reference point for quarterly procedure tallies through the end of the year.

Bright Spots in the Quarter

There were positives. Intuitive placed 546 da Vinci systems, up 28% from a year earlier. Ion procedure volume grew 31%, and instruments and accessories revenue rose 18% to $1.8 billion. System placements add to the installed base that generates those recurring instrument sales, and Ion's growth gives the company a second procedure line building alongside da Vinci.

Competition and Market Backdrop

Competition is also in the picture. Johnson & Johnson's Ottava system won regulatory approval in July, and Medtronic's Hugo system was cleared for urological procedures in December 2025. That timing means Intuitive's pricing reductions are arriving just as newly cleared rival platforms enter the picture, a backdrop investors will weigh alongside the new pricing details.

The broader market offered no cushion. The S&P 500 added about 0.1% and the Nasdaq gained about 0.4%, suggesting the drop was tied to company-specific news.

JPMorgan kept its Overweight rating on the stock and raised its price target to $475 after the results. Even so, shares remained down about 8% in Wednesday premarket trading, near $405. From here, court review of the settlement, the November start of the China price cut, and quarterly procedure results measured against the narrowed 14% to 15% guide offer the clearest markers for how the story develops.